Skip to content

Grail

US · GRAL #1873 by market cap Listed 2024
132.90 -4.38 -3.19%
Live - 5344 symbols - heartbeat 84s ago · 2026-10-08 08:13
Pre-market 131.85 -0.79%
After-hours 132.70 -0.15%
Overnight 131.00 -1.43%
Market cap
5.94B
P/B
2.33
EPS
-11.11
Reader sentiment Are you bullish or bearish on GRAL?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 2.46 Expensive vs history 100th percentile
5-year average 0.77 · #12 of 40 in Diagnostics & Research
P/E ratio -14.43 Cheap vs history 1st percentile
5-year average -3.49 · forward -13.37
P/S ratio 37.79 Expensive vs history 100th percentile
5-year average 13.34 · forward 31.29 · #40 of 43 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Grail (GRAL) 5.94B -13.72 2.33 0.00%
Thermo Fisher Scientific (TMO) 244.79B 35.63 4.65 0.27%
Danaher (DHR) 153.60B 38.81 2.92 0.66%
Natera (NTRA) 57.02B -293.01 31.30 0.00%
Agilent Technologies (A) 47.67B 33.35 6.47 0.60%
Waters (WAT) 42.84B 110.38 2.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value146.59 Economic moatNone UncertaintyVery High

Trading 10.3% below Morningstar's fair value estimate.

Fair value

GRAIL Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% premium over our quantitative fair value estimate of $146.59 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The firm's lack of profitability decreases our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 2.9% lies in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.

Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 10.9, for example, ranks in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:13:53 · For reference only, not investment advice and not tailored to your situation.